General information about company

Scrip code*544709
NSE Symbol*GAUDIUMIVF
MSEI Symbol*NOTLISTED
ISIN*INE0P8B01020
Name of companyGAUDIUM IVF AND WOMEN HEALTH LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2026
Date of end of financial year31-03-2027
Date of board meeting when results were approved13-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange07-08-2026
Description of presentation currencyINR
Level of roundingLakhs
Reporting TypeQuarterly
Reporting QuarterFirst quarter
Nature of report standalone or consolidatedConsolidated
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment ReportingSingle segment
Description of single segment Health Care Business
Start date and time of board meeting13-08-2026 15:30
End date and time of board meeting13-08-2026 17:30
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-04-202601-04-2026
Date of end of reporting period30-06-202630-06-2026
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations1937.661937.66
Other income112.36112.36
Total income2050.022050.02
2Expenses
(a)Cost of materials consumed00
(b)Purchases of stock-in-trade707.37707.37
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade-79.78-79.78
(d)Employee benefit expense 228.31228.31
(e)Finance costs37.6237.62
(f)Depreciation, depletion and amortisation expense72.1772.17
(g)Other Expenses
1Cost of rendering services 105.92105.92
2Other Expenses733.43733.43
Total other expenses839.35839.35
Total expenses1805.041805.04
3Total profit before exceptional items and tax244.98244.98
4Exceptional items 00
5Total profit before tax244.98244.98
6Tax expense
7Current tax64.6564.65
8Deferred tax2.742.74
9Total tax expenses67.3967.39
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations177.59177.59
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method00
16Total profit (loss) for period177.59177.59
17Other comprehensive income net of taxes2.412.41
18Total Comprehensive Income for the period180180
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital3639.343639.34
Face value of equity share capital55
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations0.250.25
Diluted earnings (loss) per share from continuing operations0.250.25
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations0.250.25
Diluted earnings (loss) per share from continuing and discontinued operations0.250.25
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Text Block

Textual Information(4)NOTES TO UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

1.The unaudited consolidated financial results of the Company for the quarter ended 30 June 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 August 2026. The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 (“the Regulations”), as amended and expressed an unmodified conclusion.

2.The unaudited consolidated financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting”, prescribed under Section 133 of the Companies Act, 2013 (“the Act”) read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in terms of the Regulations.

3.The figures for the quarter ended 31 March 2026 represents the derived figures between the audited figures in respect of full financial year ended 31 March 2026 and the unaudited published year-to-date figures upto 31 December 2025, being the date of the end of third quarter of the financial year which were subjected to limited review by the statutory auditor of the Company.

4.The Group has a single business segments 'Health Care Business' as per Ind AS 108 on ‘Operating Segments’.

5.Other income includes interest on fixed deposit amounting to Rs. 102.24 lakhs for the quarter ended 30 June 2026 (31 March 2026: interest on fixed deposit of Rs. 7.96 lakhs, 30 June 2025: interest on fixed deposit is nil, year ended 31 March 2026: interest on fixed deposit of Rs. 7.96 lakhs).

6.During the Financial Year 2025-26, the Company completed its Initial Public Offer (IPO) of 2,08,86,200 equity shares of face value of Rs.5 each at an issue price of Rs.79 per share (including a share premium of Rs.74 per share). The issue comprised of a fresh issue of 1,13,92,500 equity shares aggregating to Rs.9,000.08 Lakhs and an offer for sale of 94,93,700 equity shares by the selling shareholder aggregating to Rs.7,500.02 Lakhs. The equity shares of the Company were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on February 27, 2026.

Utilisation of IPO proceeds (Rs in Lakhs) is as follows. For Funding capital expenditure towards establishment of New IVF Centers of our Company amount to be utilised as per prospectus is 5000.00 Lakhs and amount utilised till June 30 2026 is 102.95 Lakhs and amount remaining unutilized as on June 30 2026 is 4897.05 Lakhs. For Repayment or pre payment in full or in part of certain outstanding loans availed by our Company amount to be utilised as per prospectus is 2000.00 Lakhs and amount utilised till June 30 2026 is 1807.37 Lakhs and amount remaining unutilized as on June 30 2026 is 192.63 Lakhs. For General Corporate Purposes amount to be utilised as per prospectus is 1228.19 Lakhs and amount utilised till June 30 2026 is 721.02 Lakhs and amount remaining unutilized as on June 30 2026 is 507.17 Lakhs. For Fresh issue related expenses amount to be utilised as per prospectus is 771.89 Lakhs and amount utilised till June 30 2026 is 771.89 Lakhs and amount remaining unutilized as on June 30 2026 is Nil. Interest on Fixed Deposit as on June 30 2026 is 14.71 Lakhs. The Total amount to be utilised as per prospectus is 9000.08 Lakhs. Total amount utilised till June 30 2026 is 3403.23 Lakhs and Total amount remaining unutilized is 5611.56 Lakhs.


7.Items of expenditure which exceed 10% of total expenditure are as given below.
For Sales and marketing expenses the amount for the Quarter ended June 30 2026 is 404.33 Lakhs and amount for the Quarter ended March 31 2026 is 236.70 Lakhs and amount for the Quarter ended June 30 2025 is 162.72 Lakhs and amount for the Year ended March 31 2026 is 684.97 Lakhs. For Rent the amount for the Quarter ended June 30 2026 is 72.12 Lakhs and amount for the Quarter ended March 31 2026 is 67.64 Lakhs and amount for the Quarter ended June 30 2025 is 64.32 Lakhs and amount for the Year ended March 31 2026 is 267.76 Lakhs. For Legal and professional fees the amount for the Quarter ended June 30 2026 is 146.95 Lakhs and amount for the Quarter ended March 31 2026 is 95.71 Lakhs and amount for the Quarter ended June 30 2025 is 140.27 Lakhs and amount for the Year ended March 31 2026 is 266.71 Lakhs.

8.The above unaudited consolidated financial results are available on the Company’s website (www.gaudiumivfcentre.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.



Other Comprehensive Income

Date of start of reporting period01-04-202601-04-2026
Date of end of reporting period30-06-202630-06-2026
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1Items that will not be reclassified to the Statement of Profit and Loss3.223.22
Total Amount of items that will not be reclassified to profit and loss3.223.22
2Income tax relating to items that will not be reclassified to profit or loss 0.810.81
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss 0.000.00
5Total Other comprehensive income2.412.41